Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...

Don't kill the messenger RNA! First mRNA stabilizing substance could open new ways in the development of innovative mRNA therapeutics Date: October 16, 2024 Source: Max Planck Institute of ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

A commonly used strategy in the development of messenger RNA (mRNA) medicine is based on the destruction of disease-causing mRNA. Achieving the opposite and stabilizing health-promoting mRNA is ...

Curevac N.V. ( (CVAC) ) has released its Q3 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. CureVac ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines ...

Cells synthesise messenger RNA (mRNA) using instructions in DNA and then ‘read’ instructions from the mRNA to make functional ...